<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6925545/results/search/drug/results.xml">
  <result pre="from 84% before the year 2000 to 30% in 2013.7" exact="Ganciclovir" post="(GCV) can reduce EBV replication, but neither ganciclovir/foscarnet (FCV)"/>
  <result pre="(GCV) can reduce EBV replication, but neither ganciclovir/foscarnet (FCV) nor" exact="cidofovir" post="(CDV) therapy/prophylaxis have any impact on development of EBV-PTLD,"/>
  <result pre="Therapies Pharmacotherapy Survival (%) CMV* 256 214 42 0 250" exact="Ganciclovir" post="(n=218) 93.9 Foscarnet (n=84) Cidofovir (n=31) Valganciclovir (n=25) IVIG"/>
  <result pre="256 214 42 0 250 Ganciclovir (n=218) 93.9 Foscarnet (n=84)" exact="Cidofovir" post="(n=31) Valganciclovir (n=25) IVIG (n=11) Acyclovir (n=1) CMV-CTL (n=1)"/>
  <result pre="42 0 250 Ganciclovir (n=218) 93.9 Foscarnet (n=84) Cidofovir (n=31)" exact="Valganciclovir" post="(n=25) IVIG (n=11) Acyclovir (n=1) CMV-CTL (n=1) BKV* 181"/>
  <result pre="Acyclovir (n=1) CMV-CTL (n=1) BKV* 181 176 5 5 96" exact="Cidofovir" post="(n=71) 90.7 Ciprofloxacin (n=18) Ganciclovir (n=11) Foscarnet (n=10) IVIG"/>
  <result pre="(n=1) BKV* 181 176 5 5 96 Cidofovir (n=71) 90.7" exact="Ciprofloxacin" post="(n=18) Ganciclovir (n=11) Foscarnet (n=10) IVIG (n=5) EBV* 175"/>
  <result pre="181 176 5 5 96 Cidofovir (n=71) 90.7 Ciprofloxacin (n=18)" exact="Ganciclovir" post="(n=11) Foscarnet (n=10) IVIG (n=5) EBV* 175 168 7"/>
  <result pre="(n=5) EBV* 175 168 7 2 143 Rituximab (n=143) 93.4" exact="Cidofovir" post="(n=2) ADV* 85 79 6 10 51 Cidofovir (n=48)"/>
  <result pre="(n=143) 93.4 Cidofovir (n=2) ADV* 85 79 6 10 51" exact="Cidofovir" post="(n=48) 90.3 Ganciclovir (n=5) Foscarnet (n=1) RV 37 37"/>
  <result pre="(n=2) ADV* 85 79 6 10 51 Cidofovir (n=48) 90.3" exact="Ganciclovir" post="(n=5) Foscarnet (n=1) RV 37 37 0 19 0"/>
  <result pre="92.8 HHV-6* 10 9 1 1 10 Foscarnet (n=5) 100.0" exact="Ganciclovir" post="(n=5) Cidofovir (n=1) VZV* 9 9 0 0 9"/>
  <result pre="10 9 1 1 10 Foscarnet (n=5) 100.0 Ganciclovir (n=5)" exact="Cidofovir" post="(n=1) VZV* 9 9 0 0 9 Aciclovir (n=9)"/>
  <result pre="(n=1) RSV* 5 5 0 1 5 IVIG (n=3) 100.0" exact="Ribavirin" post="(n=2) Ganciclovir (n=2) RhV 4 3 1 4 0"/>
  <result pre="5 5 0 1 5 IVIG (n=3) 100.0 Ribavirin (n=2)" exact="Ganciclovir" post="(n=2) RhV 4 3 1 4 0 - 100.0"/>
  <result pre="4 0 - 100.0 HPIV* 3 3 0 0 3" exact="Ribavirin" post="(n=2) 66.7 Ganciclovir (n=2) IVIG (n=1) HSV 2 2"/>
  <result pre="100.0 HPIV* 3 3 0 0 3 Ribavirin (n=2) 66.7" exact="Ganciclovir" post="(n=2) IVIG (n=1) HSV 2 2 0 0 2"/>
  <result pre="2 Aciclovir (n=2) 100.0 hMPV 1 1 0 0 1" exact="Ganciclovir" post="(n=1) 100.0 PVB19 1 1 0 1 0 –"/>
  <result pre="were treated with antiviral drugs, including: CDV (n=18), GCV (n=17)," exact="aciclovir" post="(ACV) (n=1), oseltamivir (n=1) or drug combinations (FCV+GCV, n=5;"/>
  <result pre="risk of clinically significant CMV infection.18 We have shown that" exact="ganciclovir" post="and foscarnet were the most frequently used drugs in"/>
  <result pre="disease is a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir," exact="leflunomide" post="or artesunate can be considered in patients resistant or"/>
  <result pre="a challenge. Combination therapy (ganciclovir and foscarnet), cidofovir, leflunomide or" exact="artesunate" post="can be considered in patients resistant or refractory to"/>
  <result pre="severity, and the selection of antibiotic resistance.19 In our study" exact="cidofovir" post="was the most frequently used drug in the treatment"/>
  <result pre="most frequently used drug in the treatment of BKV infection." exact="Cidofovir" post="at a dose of 3–5 mg/kg every 1–2 weeks"/>
  <result pre="with available antiviral drugs is currently not recommended and intravenous" exact="cidofovir" post="is currently regarded as a standard of care in"/>
  <result pre="were acquired during hospitalization.17 In the case of CARV infections," exact="ribavirin" post="and intravenous immunoglobulin are recommended in hMPV, HPIV and"/>
  <result pre="immunoglobulins also have no impact in PTLD. Neither ganciclovir/foscarnet nor" exact="cidofovir" post="therapy/prophylaxis have any impact on the development of EBV-PTLD,"/>
 </snippets>
</snippetsTree>
